000156956 001__ 156956
000156956 005__ 20240229123124.0
000156956 0247_ $$2doi$$a10.1186/s13014-020-01571-x
000156956 0247_ $$2pmid$$apmid:32471500
000156956 0247_ $$2pmc$$apmc:PMC7260752
000156956 0247_ $$2altmetric$$aaltmetric:83214619
000156956 037__ $$aDKFZ-2020-01261
000156956 041__ $$aeng
000156956 082__ $$a610
000156956 1001_ $$aHoffmann, Aswin$$b0
000156956 245__ $$aMR-guided proton therapy: a review and a preview.
000156956 260__ $$aLondon$$bBioMed Central$$c2020
000156956 3367_ $$2DRIVER$$aarticle
000156956 3367_ $$2DataCite$$aOutput Types/Journal article
000156956 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1594287791_24515$$xReview Article
000156956 3367_ $$2BibTeX$$aARTICLE
000156956 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156956 3367_ $$00$$2EndNote$$aJournal Article
000156956 520__ $$aThe targeting accuracy of proton therapy (PT) for moving soft-tissue tumours is expected to greatly improve by real-time magnetic resonance imaging (MRI) guidance. The integration of MRI and PT at the treatment isocenter would offer the opportunity of combining the unparalleled soft-tissue contrast and real-time imaging capabilities of MRI with the most conformal dose distribution and best dose steering capability provided by modern PT. However, hybrid systems for MR-integrated PT (MRiPT) have not been realized so far due to a number of hitherto open technological challenges. In recent years, various research groups have started addressing these challenges and exploring the technical feasibility and clinical potential of MRiPT. The aim of this contribution is to review the different aspects of MRiPT, to report on the status quo and to identify important future research topics.Four aspects currently under study and their future directions are discussed: modelling and experimental investigations of electromagnetic interactions between the MRI and PT systems, integration of MRiPT workflows in clinical facilities, proton dose calculation algorithms in magnetic fields, and MRI-only based proton treatment planning approaches.Although MRiPT is still in its infancy, significant progress on all four aspects has been made, showing promising results that justify further efforts for research and development to be undertaken. First non-clinical research solutions have recently been realized and are being thoroughly characterized. The prospect that first prototype MRiPT systems for clinical use will likely exist within the next 5 to 10 years seems realistic, but requires significant work to be performed by collaborative efforts of research groups and industrial partners.
000156956 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000156956 588__ $$aDataset connected to CrossRef, PubMed,
000156956 7001_ $$aOborn, Bradley$$b1
000156956 7001_ $$aMoteabbed, Maryam$$b2
000156956 7001_ $$aYan, Susu$$b3
000156956 7001_ $$aBortfeld, Thomas$$b4
000156956 7001_ $$aKnopf, Antje$$b5
000156956 7001_ $$aFuchs, Herman$$b6
000156956 7001_ $$aGeorg, Dietmar$$b7
000156956 7001_ $$0P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe$$aSeco, Joao$$b8$$udkfz
000156956 7001_ $$aSpadea, Maria Francesca$$b9
000156956 7001_ $$0P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aJäkel, Oliver$$b10$$udkfz
000156956 7001_ $$aKurz, Christopher$$b11
000156956 7001_ $$00000-0001-7779-6690$$aParodi, Katia$$b12
000156956 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-020-01571-x$$gVol. 15, no. 1, p. 129$$n1$$p129$$tRadiation oncology$$v15$$x1748-717X$$y2020
000156956 909CO $$ooai:inrepo02.dkfz.de:156956$$pVDB
000156956 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000156956 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000156956 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000156956 9141_ $$y2020
000156956 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-01-12
000156956 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-12
000156956 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-12
000156956 9201_ $$0I:(DE-He78)E041-20160331$$kE041$$lE041 Medizinische Physik in der Radioonkologie$$x0
000156956 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x1
000156956 980__ $$ajournal
000156956 980__ $$aVDB
000156956 980__ $$aI:(DE-He78)E041-20160331
000156956 980__ $$aI:(DE-He78)E040-20160331
000156956 980__ $$aUNRESTRICTED